AMGN vs. GSK: Amgen vs. GSK Stock Comparison

Company Profile

Amgen (AMGN) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AMGN is classified in Biotechnology while GSK is classified in Pharmaceuticals.

Amgen (AMGN) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Amgen (AMGN) at 78.35% and GSK (GSK) at 28.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.

Both Amgen (AMGN) at 35.79% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Amgen (AMGN) at 9.95% and GSK (GSK) at 4.11% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Amgen (AMGN) at 88.23% and GSK (GSK) at 123.15% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both Amgen (AMGN) at 1.48 and GSK (GSK) at 0.86 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: GSK (GSK) at 1.30 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Amgen (AMGN) at 2.16% and GSK (GSK) at 1.57% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Amgen (AMGN) at 57.62% and GSK (GSK) at 63.33% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Amgen (AMGN) at 26.69 and GSK (GSK) at 17.54 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Amgen (AMGN) at 6.40 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

GSK (GSK) at 4.02 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

Valuation Metrics